

BIONTECH

We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious and rare diseases:

Oncology

Drug Class	Platform	Product Candidate	Indication (Targets)	Preclinical	Phase 1	Phase 2	Phase 3	Rights/ Collaborator
mRNA	FixVac (fixed combination of shared cancer antigens)	BNT111	Advanced Melanoma (Adjuvant & Metastatic)					Global
		BNT112	Prostate Cancer					Global
		BNT113	HPV+ Head and Neck Cancer ¹					Global
		BNT114	Triple Negative Breast Cancer					Global
		BNT115	Ovarian Cancer ¹					Global
		BNT116	NSCLC					Global
	iNeST (patient specific cancer antigen therapy)	RO7198457 (BNT122)	1L Melanoma with CPI ²					Genentech (Global 50:50 profit/loss share)
			Multiple Solid Tumors					
	Intratumoral Immunotherapy	SAR441000 (BNT131)	Solid Tumors (IL-12sc, IL-15sushi, GM-CSF, IFN α)					Sanofi (Global profit/loss share)
		RiboMabs (mRNA-encoded antibodies)	BNT141	Multiple Solid Tumors				
	BNT142		Multiple Solid Tumors (CD3+CLDN6)					Global
	RiboCytokines (mRNA-encoded cytokines)	BNT151	Multiple Solid Tumors (Optimized IL-2)					Global
BNT152, BNT153		Multiple Solid Tumors (IL-7, IL-2)					Global	
Engineered Cell Therapies	CAR-T Cells	BNT211	Multiple Solid Tumors (CLDN6)					Global
		BNT212	Pancreatic, Other Cancers (CLDN18.2)					Global
	TCRs	To be selected	Solid Tumors					Eli Lilly (Exclusive license option)
		To be selected	All Tumors					Global
Antibodies	Next-Gen CP³ Immunomodulators	GEN1046 (BNT311)	Multiple Solid Tumors (PD-L1x4-1BB)					Genmab (Global 50:50 profit/loss share)
		GEN1042 (BNT312)	Multiple Solid Tumors (CD40x4-1BB)					
	Targeted Cancer Antibodies	MVT-5873 (BNT321)	Pancreatic Cancer (sLe ^a)					Global
SM Immunomodulators	Toll-Like Receptor Binding	BNT411	Solid Tumors (TLR7)					Global

Other

Drug Class	Platform	Product Candidate	Indication (Targets)	Preclinical	Phase 1	Phase 2	Phase 3	Rights/ Collaborator
mRNA	Infectious Disease Immunotherapies	BNT161	Influenza					Pfizer
		To be selected	Up to 10 Indications					Penn ⁴
	To be selected	HIV					Bill & Melinda Gates Foundation	
	To be selected	Tuberculosis					Bill & Melinda Gates Foundation	
	Rare Disease PRT⁵	To be selected	5 Rare Disease Indications					Genevant (Global 50:50 profit/loss share)

¹ BNT113 and BNT115 are currently being studied in investigator-initiated phase 1 trials

² Checkpoint Inhibitor

³ Checkpoint

⁴ We are eligible to receive worldwide licenses

⁵ Protein Replacement Therapy